How profitable is Anbio Biotechnology (Class A) (NNNN)?

In FY 2025 (10-K), NNNN converted $8.6M of revenue into a 87.2% gross margin, 66.7% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / NNNN / financials

TKNO (42) MYGN (47) ACHV (39) QDEL (21) ⌘ Pro Terminal →

Anbio Biotechnology (Class A) (NNNN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.51 +4.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.53

Anbio Biotechnology (Class A) (NNNN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $483.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NNNN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.51 (+4.46% 1D, market cap $483.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NNNN ranks #593 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NNNN compare to TKNO and MYGN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D- (35/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, TKNO (Alpha Teknova Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $454.1M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NNNN?

▼

Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.53 (+0.61%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNNN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY NNNN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 87.2% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.26-12.4% Next Q

Q2 (-2Q)

Grade D$3.73-0.5% Next Q

Q3 (-1Q)

Grade E$3.71-5.4% Next Q

Current

Grade D-$3.51-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NNNN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NNNN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.32) and Max Pain ($3.69) forces dealer call-delta covering toward $46.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NNNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NNNN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $6.7M

FY24

Rev $8.2M

FY25

Rev $8.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$8.6M	87.2%	66.7%	$6.4M	-$6.7M	20.4%
FY 2024	$8.2M	71.9%	24.4%	$2.4M	$2.1M	29%
FY 2023	$6.7M	87.2%	29.2%	$2.3M	$898.4K	17%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNNN)

✓Walkthrough of NNNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NNNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.29%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.72H $3.72L $3.36C $3.51VOL 39.0K

RES: $7.38SUP: $1.89SMA50: $5.32SMA200: $17.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NNNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NNNN Butterfly Map → + Track NNNN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +5.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NNNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NNNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NNNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNNN)

Health Care Rank #593 of 1015 ⚔️ TKNO vs NNNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NNNN vs. TKNO, MYGN, ACHV, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Anbio Biotechnology (Class A) (NNNN) ranks #593 by composite RQD confidence (35/100, grade D-) and #450 by equity capitalization ($483.5M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NNNN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NNNN ACTIVE Anbio Biotechnology (Class A)	D-	35/100	83.6x	87.2%	17.0%	+4.46%	$483.5M	Benchmark Subject
TKNO Alpha Teknova Inc.	D-	42/100	—	33.2%	-21.3%	-4.75%	$454.1M	/tkno-vs-nnnn →
MYGN Myriad Genetics Inc.	D	47/100	—	69.9%	-35.0%	-7.87%	$607.4M	/mygn-vs-nnnn →
ACHV Achieve Life Sciences Inc.	D-	39/100	—	—	-35.0%	-3.22%	$702.8M	/achv-vs-nnnn →
QDEL QuidelOrtho Corporation	E	21/100	—	—	-35.0%	+5.89%	$908.6M	/qdel-vs-nnnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001982708 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported GAAP revenue of $8.6M (+5.6% vs. FY2024 revenue of $8.2M , and +28.8% cumulative change since FY2023) , GAAP net income of $6.4M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (-423.9% YoY). On the balance sheet, NNNN closed FY2025 with $30.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.6M	$6.4M	-$6.7M	-$6.7M	$30.2M	—
FY2024 (FY)	2024-12-31	$8.2M	$2.4M	$2.1M	$2.1M	$18.9M	—
FY2023 (FY)	2023-12-31	$6.7M	$2.3M	$898.4K	$898.4K	—	—

3. NNNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NNNN compare to TKNO and MYGN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NNNN?

Where is NNNN trading relative to its 50-day, 200-day, and 52-week technical levels?

NNNN last traded at $3.51 (+4.46% on volume of 56,470 shares), positioning the stock -34.02% below its 50-day simple moving average ($5.32) and -79.39% below its 200-day simple moving average ($17.03). Across its 52-week range of $3.09 to $44.73, NNNN sits at the 1.0% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.07 to $3.95).

Direct Sub-Reports: NNNN RQD Cockpit NNNN 12M Forecast NNNN Earnings & Move NNNN Dividends & DRIP NNNN Insiders & 13F NNNN Whale Options NNNN Profit Sankey NNNN News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

NNNN — Anbio Biotechnology (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Anbio Biotechnology (Class A) (NNNN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.51 (+4.46% 1D, market capitalization $483.5M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 17.0%, gross margin of 87.2%, operating margin of 66.7%, and free cash flow yield of -1.26%.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Anbio Biotechnology (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile does not describe its specific products, customers, or revenue model. Per the market data, the company reports a gross margin of 87.2%, an operating margin of 66.7%, and a net margin of 68%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported $8.6M in annual revenue (up from $8.2M in FY2024, +5.6% YoY) and $6.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.7M revenue, $2.3M net income) through FY2025, NNNN scaled operating cash flow to -$6.7M and free cash flow to -$6.7M, backed by $30.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.26% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.09 – $44.73 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 83.6x trailing P/E and 91.5x EV/EBITDA against 66.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The sector classification (Health Care) and industry classification (In Vitro & In Vivo Diagnostic Substances) are the only available context for ripple analysis.

Key Question #1: Can NNNN sustain or expand its 66.7% operating margin and 17.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $8.6M and free cash flow of -$6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NNNN's 77.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NNNN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Anbio Biotechnology (Class A) (NNNN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NNNN Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

Anbio Biotechnology Estimates – NASDAQ:NNNN

TradingView report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Tuesday's Intraday Session - SCWorx (NASDAQ:WORX), Myriad Genetics (NASDA

Benzinga report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Femasys Inc. (FEMY) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Anbio Biotechnology (NNNN) Climbs 3.50% to $3.84 as Buyers Test Upper Range - NHNL Ratio

https://www.siam.in/ report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Synsam AB (publ) (SYNSAM.ST) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH ChartMill • 14d ago

Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session

Top gainers rose as much as 55.88% and top losers fell as much as 53.13% in today's session, led by PRSO, BRZE, CJMB, and SXTC.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NNNN Bull vs. Bear Conversation Board — What's Your Call at $3.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NNNN 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.03 (+19.9%)

📌 Pinned Debate

Reported FY 2025 net income of $6.4M and a 66.7% operating margin show strong profitability, supported by a 17% ROIC.

Long NNNN at $3.36 targeting $4.03. Reported FY 2025 net income of $6.4M and a 66.7% operating margin show strong profitability, supported by a 17% ROIC.. Institutional whale score is 3/20 and the risk/reward vs. the $3.09 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@MultipleCompression Fair point on 83.6x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: In Vitro & In Vivo Diagnostic Substances. If gross margin (87.2%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.89 (-14.0%)

Spot @ $3.36

Negative FCF of -$6.7M in FY 2025 and a P/E (TTM) of 83.6 leave the price resting on earnings the cash flows do not yet confirm.

Fading this rally in NNNN at $3.36. Negative FCF of -$6.7M in FY 2025 and a P/E (TTM) of 83.6 leave the price resting on earnings the cash flows do not yet confirm.. With a beta of 1.0 and the stock sitting at $3.36 (52-wk range $3.09–$44.73), the easy multiple expansion is already priced in.